Caribou_logo.png
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
25 sept. 2024 09h00 HE | Caribou Biosciences, Inc.
BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract...
Caribou_logo.png
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
03 sept. 2024 08h00 HE | Caribou Biosciences, Inc.
-- Fast Track designation is designed to expedite clinical development and regulatory review timelines -- -- Additional FDA designation for CB-010 following earlier RMAT and Fast Track...
Caribou_logo.png
Caribou Biosciences to Participate in Upcoming Investor Conferences
26 août 2024 16h00 HE | Caribou Biosciences, Inc.
BERKELEY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced company...
tina-albertson
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
12 août 2024 08h00 HE | Caribou Biosciences, Inc.
-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE...
Caribou_logo.png
Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
06 août 2024 16h05 HE | Caribou Biosciences, Inc.
-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; clinical data reports planned for 2024 and H1 2025 -- -- Enrolling 2L LBCL and prior CD19 relapsed LBCL...
Caribou_logo.png
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
09 juil. 2024 08h00 HE | Caribou Biosciences, Inc.
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences,...
PFS image_Caribou Biosciences
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
02 juin 2024 19h00 HE | Caribou Biosciences, Inc.
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER...
Caribou_logo.png
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
30 mai 2024 16h01 HE | Caribou Biosciences, Inc.
BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Caribou_logo.png
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
07 mai 2024 16h05 HE | Caribou Biosciences, Inc.
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into...
Caribou_logo.png
Caribou Biosciences to Participate in Upcoming Investor Conferences
01 mai 2024 16h05 HE | Caribou Biosciences, Inc.
BERKELEY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...